We are live on ! Find out more
GNBT

GENEREX BIOTECHNOLOGY CORP
GNBT

Delisted

GNBT was delisted on the 20th of October, 2010.

Back to rankings

2 hedge funds and large institutions have $2.04K invested in GENEREX BIOTECHNOLOGY CORP in 2014 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more capital invested

Capital invested by funds: $1.56K → $2.04K (+$489)

33% less funds holding

Funds holding: 3 → 2 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

GNBT Hedge Fund Activity: Q1 2014 in Review

2 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in GENEREX BIOTECHNOLOGY CORP (GNBT) for Q1 2014, worth a combined $2.04K — up 31% from $1.56K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of GNBT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

  • 2 institutional investors held GENEREX BIOTECHNOLOGY CORP (GNBT) as of Q1 2014, down from 3 in Q4 2013.
  • Funds reported $2.04K of GENEREX BIOTECHNOLOGY CORP stock for Q1 2014, up 31% quarter-over-quarter.
  • 0 funds opened new GENEREX BIOTECHNOLOGY CORP positions in Q1 2014 and 1 closed out, a net change of -1 holder.

Based on aggregated 13F filings for Q1 2014.